New biomarker can accurately predict outcomes in meningiomas and breast cancers
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately ...
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...
The EMBO Journal19h
Transcriptional enhancers in human neuronal differentiation provide clues to neuronal disorders
This study identifies 47,350 enhancers active in human neurons during differentiation and links some to genes involved in ...
UroToday6h
ASCO GU 2025: Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase 2 Multi-arm Biomarker-Based Study (Alliance A032102)
The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.